Cronenwett J L, Birkmeyer J D, Nackman G B, Fillinger M F, Bech F R, Zwolak R M, Walsh D B
Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, NH 03756, USA.
J Vasc Surg. 1997 Feb;25(2):298-309; discussion 310-1. doi: 10.1016/s0741-5214(97)70351-3.
The purpose of this study was to determine the cost-effectiveness of carotid endarterectomy for treating asymptomatic patients with > or = 60% internal carotid stenosis, based on outcomes reported in the Asymptomatic Carotid Atherosclerosis Study (ACAS).
A cost-effectiveness analysis was performed using a Markov decision model in which the probabilities for base-case analysis (average age, 67 years; 66% male; perioperative stroke plus death rate, 2.3%; ipsilateral stroke rate during medical management, 2.3% per year) were based on ACAS. The model assumed that patients who had TIAs or minor strokes during medical management crossed over to surgical treatment, and used the NASCET data to model the outcome of these now-symptomatic patients. Average cost of surgery ($8500), major stroke ($34,000 plus $18,000 per year), and other costs were based on local cost determinations plus a review of the published literature. Cost-effectiveness was calculated as the incremental cost of surgery per quality-adjusted life year (QALY) saved when compared with medical treatment, discounting at 5% per year. Sensitivity analysis was performed to determine the impact of key variables on cost-effectiveness.
In the base-case analysis, surgical treatment improved quality-adjusted life expectancy from 7.87 to 8.12 QALYs, at an incremental lifetime cost of $2041. This yielded an incremental cost-effectiveness ratio of $8,000 per QALY saved by surgical compared with medical treatment. The high cost of care after major stroke during medical management largely offset the initial cost of endarterectomy in the surgical group. Furthermore, 26% of medically managed patients eventually underwent endarterectomy because of symptom development, which also decreased the cost differential. Sensitivity analysis demonstrated that the relative cost of surgical treatment increased substantially with increasing age, increasing perioperative stroke rate, and decreasing stroke rate during medical management.
For the typical asymptomatic patient in ACAS with > or = 60% carotid stenosis, our results indicate that carotid endarterectomy is cost-effective when compared with other commonly accepted health care practices. Surgery does not appear cost-effective in very elderly patients, in settings where the operative stroke risk is high, or in patients with very low stroke risk without surgery.
本研究旨在根据无症状颈动脉粥样硬化研究(ACAS)报告的结果,确定颈动脉内膜切除术治疗无症状性颈内动脉狭窄≥60%患者的成本效益。
使用马尔可夫决策模型进行成本效益分析,其中基础病例分析的概率(平均年龄67岁;男性66%;围手术期卒中加死亡率2.3%;药物治疗期间同侧卒中率每年2.3%)基于ACAS。该模型假设在药物治疗期间发生短暂性脑缺血发作(TIA)或轻度卒中的患者转而接受手术治疗,并使用北美症状性颈动脉内膜切除术试验(NASCET)数据对这些现已出现症状的患者的结局进行建模。手术平均成本(8500美元)、重度卒中(34000美元加每年18000美元)及其他成本基于当地成本测定以及对已发表文献的回顾。成本效益计算为与药物治疗相比,手术每挽救一个质量调整生命年(QALY)的增量成本,按每年5%进行贴现。进行敏感性分析以确定关键变量对成本效益的影响。
在基础病例分析中,手术治疗将质量调整预期寿命从7.87个QALY提高到8.12个QALY,终身增量成本为2041美元。这产生了与药物治疗相比,手术每挽救一个QALY增量成本效益比为8000美元。药物治疗期间重度卒中后的高护理成本在很大程度上抵消了手术组内膜切除术的初始成本。此外,26%接受药物治疗的患者最终因症状发展而接受了内膜切除术,这也缩小了成本差异。敏感性分析表明,随着年龄增加、围手术期卒中率增加以及药物治疗期间卒中率降低,手术治疗的相对成本大幅增加。
对于ACAS中典型的无症状性颈动脉狭窄≥60%的患者,我们的结果表明,与其他普遍接受的医疗保健做法相比,颈动脉内膜切除术具有成本效益。在非常老年的患者、手术卒中风险高的情况下或无手术时卒中风险非常低的患者中,手术似乎不具有成本效益。